Placebo Response in Two Long-Term Randomized Psoriasis Studies that were Negative for Rosiglitazone

Ellis, Charles N.; Barker, Jonathan; Haig, Ann; Parker, Christine A.; Daly, Susan; Jayawardene, Deepthi

doi:10.2165/00128071-200708020-00005

Cited by 37 publications

(42 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10 Nevertheless, although rosiglitazone is not active in psoriasis, one study demonstrated that the placebo effect may have an impact on the disease; a large proportion of subjects receiving placebo (with expectations of a successful treatment) showed an improvement in their skin condition. 11 This is a bias that must be taken into account in any study which may concludes this new antidiabetic agent constitutes an effective treatment.…”

Section: Discussionmentioning

confidence: 99%

Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor

Mas-Vidal¹,

Santos‐Juanes²,

Esteve‐Martínez³

et al. 2011

Aust J Dermatology

View full text Add to dashboard Cite

Psoriatic patients have a higher prevalence of diabetes mellitus type 2 (DM). Since dipeptidyl peptidase IV (DPP-IV) dysregulation is present in DM and psoriasis, DPP-IV inhibitors have been proposed as therapeutic agents for both conditions. We report a psoriasiform eruption induced by sitagliptin, a DPP-IV inhibitor. The role of DPP-IV in the pathogenesis of DM is well established; however data on psoriatic patients is contradictory. More studies are required to elucidate the effect of DPP-IV inhibitors and their relationship with DM and psoriasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor

Mas-Vidal¹,

Santos‐Juanes²,

Esteve‐Martínez³

et al. 2011

Aust J Dermatology

View full text Add to dashboard Cite

show abstract

“…A striking improvement of skin lesions had initially been documented in patients with psoriasis treated with the oral PPARg activator troglitazone (9,113). Although subsequent clinical trials using the oral PPARg activator rosiglitazone did not substantiate the initial troglitazone observation (114), favorable effects of oral pioglitazone not only on psoriatic skin lesions (10,115) but also on psoriatic arthritis (8) have been reported. An ongoing phase II trial is currently evaluating the efficacy and safety of a combination of pioglitazone with acitretin in psoriasis (NCT00395941: clinicaltrials.gov).…”

Section: Clinical Trials In Humansmentioning

confidence: 98%

Thematic Review Series: Skin Lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology

Schmuth

Jiang

Dubrac

et al. 2008

Journal of Lipid Research

184

160

View full text Add to dashboard Cite

The epidermis is a very active site of lipid metabolism, and all peroxisome proliferator-activated receptor (PPAR) and liver X receptor (LXR) isoforms are expressed in the epidermis. Activation of PPARa, -b/d, or -g or LXRs stimulates keratinocyte differentiation. Additionally, activation of these receptors also improves permeability barrier homeostasis by a number of mechanisms, including stimulating epidermal lipid synthesis, increasing lamellar body formation and secretion, and increasing the activity of enzymes required for the extracellular processing of lipids in the stratum corneum, leading to the formation of lamellar membranes that mediate permeability barrier function. The stimulation of keratinocyte differentiation and permeability barrier formation also occurs during fetal development, resulting in accelerated epidermal development. PPAR and LXR activation regulates keratinocyte proliferation and apoptosis, and studies have shown that these receptors play a role in cutaneous carcinogenesis. Lastly, PPAR and LXR activation is anti-inflammatory, reducing inflammation in animal models of allergic and irritant contact dermatitis. Because of their broad profile of beneficial effects on skin homeostasis, PPAR and LXR have great potential to serve as drug targets for common skin diseases such as psoriasis, atopic dermatitis, and skin

show abstract

“…14 In addition, rosiglitazone at 2, 4, or 8 mg/d showed some improvement of psoriasis symptoms in individual patients, even though the overall effects did not differ significantly from placebo in two larger double-blind placebocontrolled studies conducted by the manufacturer. 15 The authors of a recent review article emphasized that neither the potential clinical effectiveness of this drug class in psoriasis, nor a possible mechanism of action, are fully understood yet. 16 Little information is available on the association between other classes of oral antidiabetic drugs and psoriasis.…”

mentioning

confidence: 99%